Compare LEE & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEE | GBIO |
|---|---|---|
| Founded | 1890 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Newspapers/Magazines | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.1M | 36.3M |
| IPO Year | N/A | 2020 |
| Metric | LEE | GBIO |
|---|---|---|
| Price | $5.76 | $5.34 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.88 |
| AVG Volume (30 Days) | 42.3K | ★ 133.1K |
| Earning Date | 02-10-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $547,841,000.00 | $15,270,000.00 |
| Revenue This Year | $5.48 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.34 | $3.00 |
| 52 Week High | $12.25 | $8.40 |
| Indicator | LEE | GBIO |
|---|---|---|
| Relative Strength Index (RSI) | 66.99 | 39.79 |
| Support Level | $5.09 | $5.47 |
| Resistance Level | $5.63 | $5.77 |
| Average True Range (ATR) | 0.43 | 0.17 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 83.88 | 0.00 |
Lee Enterprises Inc is a local news publication company in the United States. It is a digital-first subscription business providing local markets with valuable, high-quality, trusted, intensely local news, information, advertising, and marketing services. The product portfolio of the company includes digital subscription platforms, daily, weekly, and monthly newspapers, and niche products, all delivering original local news and information as well as national and international news. The products offer digital and print editions, and content and advertising are available in real-time through the websites and mobile apps.
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.